Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736592 · ClinicalTrials.gov registry record · Phase 2
Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration
A Phase 2 study of Stargardt's Disease, sponsored by Sanofi.
- Active
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 2
- Study locations
NCT01736592: Active Phase 2 study of Stargardt's Disease, sponsored by Sanofi.
NCT01736592 is a Phase 2 study of Stargardt's Disease that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 27 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01736592, a Phase 2 study of Stargardt's Disease, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 2
- Study locations
Study Summary
Primary Objective: To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To assess: * Safety * Biological activity
Primary Outcome
The number and percentage of patients with treatment emergent adverse events
Conditions Studied
Interventions
- DRUG Long term follow up in all patients who received SAR422459 in previous study TDU13583
Study Locations (2)
Oregon
- Oregon Health and Science University Site Number : 840001 - Portland
Other
- Investigational Site Number : 250001 - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-12-14 |
| Est. Completion | 2033-08-29 |
| Phase | Phase 2 |
What the registry record for NCT01736592 still lists
NCT01736592 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Stargardt's Disease appearing as the primary indexed condition, and to 1 intervention - of which Long term follow up in all patients who received SAR422459 in previous study TDU13583 is the first listed.
NCT01736592 reports a single indexed study location in Oregon, Other.
Frequently Asked Questions
What is clinical trial NCT01736592 about?
NCT01736592 is a clinical study titled "Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration". Primary Objective: To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To assess: * Safety * Biological activity
What is the current status of trial NCT01736592?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2012-12-14. Estimated completion is 2033-08-29.
What conditions does trial NCT01736592 study?
This clinical trial studies the following conditions: Stargardt's Disease.
What interventions are being tested in trial NCT01736592?
The interventions under investigation include: Long term follow up in all patients who received SAR422459 in previous study TDU13583 (DRUG).
Who is sponsoring clinical trial NCT01736592?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01736592 being conducted?
This trial has 2 study locations across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01736592's enrollment target sits among peer trials
27 1697th of 2000 higher than 293 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI